The beginning of liquid biopsy in breast cancer. How an intuition became a revolution. International Society of Liquid Biopsy M JOSE SERRANO (LB&Cancer Interception group) Christian Rolfo David Gandara WCM Englander Institute for Precision Medicine Weill Cornell Medicine Meyer Cancer Center #MBC #AACR24

EGFR mutants are not a monolithic entity. In fact EGFR mutational status is heterogeneous and EGFR mutated cancers can be Dr Jekyll or Mr Hyde #AACR24 Marina Garassino

👇🏾Delighted to chair this session today AACR #AACR24 .

“Biomarkers Predictive of Therapeutic Benefit”
📍Ballroom 6 CF Convention Center
Symposia • 3:00–5:00 pm

💡Beyond targeted therapies (HER2, KRASG12C) to predictive biomarkers of immunotherapy, toxicity➕ #ctDNA .

OncoAlert

Humbled for moderating a heated session on periop trial designs at AACR , with a great panel: Harpreet Singh, MD Raymond Osarogiagbon, MBBS, FACP Dr. Elizabeth Jaffee Michael Axelson Francesco Pignatti Manju George MVSc PhD Rectal Cancer Survivor Thank you all!

Great presentation by Dr. Naidoo from Ireland from the PROPHET proteomic platform study showing interesting predictive value who will respond from IO mono versus IO+CT, particularly when combined with PD-L1 expression!

Big news across pan-tumor types. Trastuzumab Deruxtecan becomes First Tumor Agnostic HER2-Targeted Treatment Approved (IHC3+) insideprecisionmedicine.com/topics/oncolog… via @clinicalomics

Terrific presentation by Jarushka Naidoo representing the team science behind using proteomics to predict immune related adverse events in patients receiving immunotherapy #AACR24 Sidney Kimmel Cancer Center – Jefferson Health Thomas Jefferson University Jefferson Health OncoHost David Gandara

#AACR24 . Special FDA-directed Session on “Perioperative Pandemonium” going on now. Opening statement (given the explosive number of completed and developing trials in this space: “The greatest concern is over-treatment” for some patients. Food for thought AACR FDA Oncology

Extraordinary work that hopefully will translate into clinical applications! Thanks Charles Swanton for sharing in this Tweetorial.

✨No More, No Less✨
Perioperative Pandemonium
Trial Designs in Early Stage Solid Tumors FDA Oncology

Dr Dr. Nagla Abdel Karim presenting follow up on S1929 as the first integral Biomarker study in ES-SCLC with maintenance PARP with Atezo vs Atezo David Gandara Krishna Soujanya Gunturu MD Jhanelle Gray MD Triparna Sen (Sen-Lab) Sonam Puri MD Anne Chiang SWOG Cancer Research Network

Published in Cancer Discovery ahead of #AACR24 our vision for pushing the boundaries of #liquidbiopsies through transformative technologies and clinical implementation for early precision intervention.
Victor Velculescu Johns Hopkins Thoracic Oncology AACR
doi.org/10.1158/2159-8…

Congratulations Maya K. Khalil, MD Aakash Desai, MD, MPH 💪on leading underrepresented population accruals on SWOG Cancer Research Network #LUNG -PRAGMATICA!!
The Hope Foundation for Cancer Research !! Need representation of other pts as well! Dr. Nagla Abdel Karim Anne Chiang Krishna Soujanya Gunturu MD Jhanelle Gray MD David Gandara

Trying to develop more concepts ⁦SWOG Cancer Research Network⁩ ⁦David Gandara⁩ ⁦Triparna Sen (Sen-Lab)⁩ ⁦Sonam Puri MD⁩ ⁦Evan Wu⁩ #lungcancer ⁦Jhanelle Gray MD⁩

Join us at AACR! - Sunday at 1pm
Perioperative Pandemonium: Trial Designs in Solid Tumors✨ Moderated by Bernardo Haddock Lobo Goulart FDA Oncology AACR

Lung cancer in never-smokers represent the 5thleading cause of cancer-related mortality in the world. They are highly enriched for targetable oncogenic alterations, have low TMB, low rates of PD-L1 positivity, & lack mutational signatures. They occur almost exclusively as…

At #TTLC24 , @annechiangmd and Stephen V Liu, MD offered differing perspectives on biomarker use in extensive-stage small cell lung cancer. Read a recap in #ILCN : bit.ly/3VBEUeG #LCSM

AACR24. Looking forward to this presentation on a plasma proteomic assay for prediction of IO-induced AEs. Meeting an unmet need. Jarushka Naidoo

Agree Dr. Antonio Calles 🫁🚭

Please Alfredo Addeo MD you are well aware that it is a misinterpretation to attribute PFS benefit based on differences in medians: “Misuse of the median”. Multiple examples. The main issues with Codebreak200 were not efficacy but rather regulatory conduct such as dropout rates.